Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29147
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMontalban, X.-
dc.contributor.authorBarone, D.-
dc.contributor.authorBroadley, S.-
dc.contributor.authorDive, D.-
dc.contributor.authorHupperts, R. M.-
dc.contributor.authorLycke, J.-
dc.contributor.authorMassacesi, L.-
dc.contributor.authorNaismith, R. T.-
dc.contributor.authorNakamura, K.-
dc.contributor.authorPandey, K.-
dc.contributor.authorSchippling, S.-
dc.contributor.authorVermersch, P.-
dc.contributor.authorWiendl, H.-
dc.contributor.authorChung, L.-
dc.contributor.authorDaizadeh, N.-
dc.contributor.authorAfsar, S.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.date.accessioned2019-09-10T14:08:57Z-
dc.date.available2019-09-10T14:08:57Z-
dc.date.issued2019-
dc.identifier.citationEUROPEAN JOURNAL OF NEUROLOGY, 26, p. 678-678-
dc.identifier.issn1351-5101-
dc.identifier.urihttp://hdl.handle.net/1942/29147-
dc.description.sponsorshipSTUDY SUPPORT: Sanofi and Bayer HealthCare Pharmaceuticals.-
dc.language.isoen-
dc.publisherWILEY-
dc.titleAlemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 29-JUL 02, 2019-
local.bibliographicCitation.conferencename5th Congress of the European-Academy-of-Neurology (EAN)-
local.bibliographicCitation.conferenceplaceOslo, NORWAY-
dc.identifier.epage678-
dc.identifier.spage678-
dc.identifier.volume26-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Montalban, X.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada. [Barone, D.] Rowan Univ, Glassboro, NJ USA. [Broadley, S.] Griffith Univ, Sch Med, Gold Coast Campus, Southport, Qld, Australia. [Dive, D.] Univ Hosp Ctr Liege, Liege, Belgium. [Hupperts, R. M.] Maastricht Univ, Med Ctr, Orbis Med Ctr, Sittard, Netherlands. [Lycke, J.] Univ Gothenburg, Gothenburg, Sweden. [Massacesi, L.] Univ Florence, Florence, Italy. [Naismith, R. T.] Washington Univ, Sch Med, St Louis, MO USA. [Nakamura, K.] Cleveland Clin, Cleveland, OH 44106 USA. [Pandey, K.] Hackensack Univ Hosp, Multiple Sclerosis Care Ctr, Hackensack, NJ USA. [Schippling, S.] Univ Hosp Zurich, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Vermersch, P.] Univ Lille, Lille, France. [Wiendl, H.] Univ Munster, Munster, Germany. [Chung, L.; Daizadeh, N.; Afsar, S.] Sanofi, Cambridge, MA USA. [Van Wijmeersch, B.] Hasselt Univ, Rehabil & MS Ctr Overpelt, BIOMED, Hasselt, Belgium.-
local.publisher.placeHOBOKEN-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000474481003051-
item.fulltextNo Fulltext-
item.contributorMontalban, X.-
item.contributorBarone, D.-
item.contributorBroadley, S.-
item.contributorDive, D.-
item.contributorHupperts, R. M.-
item.contributorLycke, J.-
item.contributorMassacesi, L.-
item.contributorNaismith, R. T.-
item.contributorNakamura, K.-
item.contributorPandey, K.-
item.contributorSchippling, S.-
item.contributorVermersch, P.-
item.contributorWiendl, H.-
item.contributorChung, L.-
item.contributorDaizadeh, N.-
item.contributorAfsar, S.-
item.contributorVAN WIJMEERSCH, Bart-
item.fullcitationMontalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S. & VAN WIJMEERSCH, Bart (2019) Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study). In: EUROPEAN JOURNAL OF NEUROLOGY, 26, p. 678-678.-
item.accessRightsClosed Access-
crisitem.journal.issn1351-5101-
crisitem.journal.eissn1468-1331-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.